ALX Oncology Holdings, Inc. (ALXO)
| Market Cap | 2.98B |
| Revenue (ttm) | 2.40M |
| Net Income (ttm) | n/a |
| Shares Out | 29.66M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $87.55 |
| Previous Close | $80.29 |
| Change ($) | 7.26 |
| Change (%) | 9.04% |
| Day's Open | 80.86 |
| Day's Range | 80.27 - 88.34 |
| Day's Volume | 223,133 |
| 52-Week Range | 28.01 - 117.45 |
BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the ...
ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.
ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only havin...
BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the C...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...
BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...
BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...
About ALXO
ALX Oncology Holdings, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
| Industry Biotechnology | IPO Date Jul 17, 2020 |
| CEO Dr. Jaume Pons Ph.D. | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol ALXO |
Analyst Forecasts
According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 98.83, which is an increase of 12.88% from the latest price.